Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Codexis turns its CodeEvolver breakthroughs into revenue isn’t easy—R&D tax credits, milestone payments, and multi-year licensing deals sprawl across hundreds of pages. If you have ever wondered, “Codexis SEC filings explained simply,” you are not alone.
Stock Titan’s AI pinpoints what matters in every document the moment it hits EDGAR. Need the Codexis quarterly earnings report 10-Q filing? We highlight enzyme-sale trends, cash-burn ratios, and collaboration revenue on a single dashboard. Curious about Codexis insider trading Form 4 transactions? Real-time alerts surface each executive stock move so you can spot patterns before the market reacts.
Our coverage spans every form:
- 10-K: Access the Codexis annual report 10-K simplified with side-by-side AI summaries that flag R&D capitalization, royalty streams, and liquidity notes.
- 10-Q: Drill into quarter-over-quarter enzyme margin shifts through our Codexis earnings report filing analysis.
- 8-K: Material agreements for ECO Synthesis scale-up? See them under Codexis 8-K material events explained.
- Form 4: Follow Codexis executive stock transactions Form 4 with real-time push updates; or search full history via Codexis Form 4 insider transactions real-time.
- DEF 14A: The Codexis proxy statement executive compensation section compares equity grants to peer biotech benchmarks.
Whether you need to model enzyme royalty cash flows, monitor financing covenants, or simply understand Codexis SEC documents with AI, our platform turns dense language into clear, actionable insights—so you spend minutes, not hours, finding the details that move the stock.
Codexis, Inc. (CDXS) reported an insider transaction by a director on a Form 4. On 11/21/2025, the reporting person sold 8,952 shares of common stock in an open-market transaction coded as "S" (sale).
The weighted average sale price was $1.5626 per share, with individual trades executed between $1.55 and $1.615. Following this sale, the reporting person beneficially owns 138,951 shares, held directly, which includes 40,983 restricted stock units.
Codexis, Inc. (CDXS) reported an equity award to its President and CEO, Alison Moore, on Form 4. On 11/13/2025 she received 85,000 shares of common stock in the form of restricted stock units, at a stated price of $0. These units vest in three equal annual installments on each anniversary of the grant date, provided she remains employed.
On the same date she was also granted a stock option for 500,000 shares of common stock at an exercise price of $1.63 per share, expiring on 11/13/2035. The option vests as to 25% of the shares on the first anniversary of the grant date and 1/48th of the original total each month thereafter, conditioned on continued employment. Following these transactions, she beneficially owns 254,332 shares, including 145,208 restricted stock units.
Codexis, Inc. (CDXS) chief scientific officer reports equity holdings in a beneficial ownership statement dated 11/07/2025. The officer directly owns 143,460 shares of Codexis common stock, including 53,266 restricted stock units that each convert into one share upon vesting. In addition, the officer holds multiple stock options covering shares of common stock with exercise prices ranging from $3.05 to $26.16 and expirations between 2030 and 2035. Some options are already fully vested and exercisable, while others vest over time based on specified schedules tied to dates from 2021 through 2026.
Codexis (CDXS): Opaleye Management Inc., as reporting person, disclosed open‑market sales of Codexis common stock on 11/12/2025. Transactions included 890,000 shares at $1.9372 and 165,000 shares at $1.962 through Opaleye, L.P., plus 27,459 shares at $1.9372 via a separately managed account. The prices are weighted averages; the shares were sold in multiple trades within disclosed ranges.
Following the reported transactions, beneficial ownership reported as indirect included 10,453,318 shares by Opaleye, L.P. and 196,012 shares by the managed account. The pricing footnotes state sales occurred across ranges of $1.9005–$1.9905 and $1.935–$2.0035, with full trade details available upon request.
Codexis (CDXS)
Codexis, Inc. (CDXS) reported an insider open‑market purchase. Director Stephen G. Dilly bought 50,000 shares of common stock on 11/11/2025 at a weighted average price of $1.8473, executed in multiple trades ranging from $1.7550 to $1.90.
After this transaction, he beneficially owns 727,053 shares, held directly. This total includes 2,000 shares acquired under the Employee Stock Purchase Plan on May 10, 2025 and 2,000 shares acquired on Nov 10, 2025.
Opaleye Management Inc., a director of Codexis (CDXS), reported open‑market sales of common stock. Transactions occurred on 11/07/2025, 11/10/2025, and 11/11/2025 at weighted average prices of $1.6968, $1.7347, and $1.7994, respectively.
Reported sale sizes included 296,682 and 10,000 shares on 11/07/2025; 205,000 and 3,318 shares on 11/10/2025; and 535,000 and 13,211 shares on 11/11/2025. Following these transactions, beneficial ownership was 11,508,318 shares indirectly through Opaleye, L.P., and 223,461 shares indirectly through a managed account.
Codexis (CDXS) filed its Q3 2025 10‑Q, reporting revenue of $8.6 million and a net loss of $19.6 million (basic and diluted loss per share $0.22). Product revenue was $6.8 million and research and development revenue was $1.8 million. Product gross margin was 64%.
Cash and cash equivalents were $25.4 million with short‑term investments of $33.4 million, totaling $58.7 million as of September 30, 2025. Long‑term debt was $39.7 million, primarily the Innovatus term loan. Operating cash use was $39.5 million for the nine‑month period; financing inflows included $17.3 million of common stock sales under the Cantor at‑the‑market agreement.
Subsequent events: in October 2025, Codexis entered an enzyme supply assurance agreement with Merck that provides a one‑time $37.8 million payment expected in Q4 2025. On November 6, 2025, the company announced a workforce reduction of approximately 24%, with an estimated $3.5 million expense expected in Q4 2025. Shares outstanding were 90,324,383 as of November 3, 2025.
Codexis, Inc. announced organizational and leadership changes. The company is implementing a workforce reduction of approximately 24% to align with its focus on the ECO Synthesis platform. It expects to recognize about $3.5 million of related expenses in the fourth quarter of 2025, paid primarily in the same period, with the reduction substantially completed by January 2026.
The Board appointed Alison Moore, Ph.D., as President and Chief Executive Officer and as a Class III director, effective November 7, 2025. Her compensation includes a $650,000 base salary, a target annual bonus of 75% of salary, 85,000 RSUs vesting over three years, and 500,000 stock options vesting over four years. Stephen Dilly will continue as Chair of the Board with annual cash fees of $110,000. Kevin Norrett entered into a separation and consulting agreement and will provide transitional services through November 6, 2026, and will receive a bonus equal to 100% of his target bonus.
Codexis (CDXS) reported an insider transaction by its Chief Financial Officer, Georgia Erbez. On 10/13/2025, she sold 6,239 shares of common stock at $2.505 per share. The filing notes the sale was made solely to satisfy tax or other government withholding obligations tied to the vesting of Restricted Stock Units.
Following the transaction, Erbez beneficially owned 70,636 shares directly, which includes 33,333 RSUs. The transaction code was listed as S, indicating a sale.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
